Witryna1 lip 2015 · Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, … WitrynaBackground IMpower010 met its primary DFS endpoint in PD-L1 TC ≥1% (SP263) stage II-IIIA NSCLC patients (pts) and all stage II-IIIA NSCLC pts (Felip, Lancet 2024). We report exploratory DFS outcomes by additional PD-L1 subgroups and EGFR/ALK status; we also assessed ctDNA status as a potential biomarker in this setting. Methods
Postoperative radiotherapy in resected N2 non ... - The Lancet Oncology
Witryna12 wrz 2024 · In IMpower010, the PD-L1 inhibitor atezolizumab significantly improved disease-free survival versus best supportive care after adjuvant chemotherapy in … Witryna8 gru 2024 · The publication in The Lancet by Felip and colleagues summarized the results of IMpower010, 1 which was a randomized phase III trial that enrolled 1280 … indexed in pubmed
Lancet:NSCLC患者への術後アテゾリズマブ投与がDFS改善に有効 (IMpower010 …
Witryna27 wrz 2024 · Felip E et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): A randomised, multicentre, open-label, phase 3 trial. Lancet 2024 Sep 20; [e-pub]. Witryna14 gru 2024 · On Oct 15, 2024, the US Food and Drug Administration approved atezolizumab (a PD-L1 inhibitor) as an adjuvant treatment for patients with completely resected stage II–III NSCLC (as shown in the IMpower010 study) and a PD-L1 expression of 1% or more in tumour cells, indexed insurance funds